KR20180044660A - Composition containing Melandrii Herba extract reducing lipid accumulation as effective component - Google Patents

Abstract

The present invention relates to a cosmetic composition for preventing or reducing cellulite containing a Melandrii herba extract as an active ingredient, wherein the Melandrii herba extract inhibits fat accumulation and has an antioxidative activity, thereby being locally applied to exhibit a slimming effect. The composition of the present invention can be used as a composition for preventing, ameliorating or treating obesity, health functional food or a pharmaceutical composition containing the Melandrii herba extract as the active ingredient.

Description

[0001] The present invention relates to a composition containing an extract of a quinquerol as an active ingredient having an effect of inhibiting fat accumulation,

The present invention relates to a composition containing an extract of Melandrii Herba having an effect of inhibiting fat accumulation as an active ingredient.

Since the 1990s, the development of the domestic economy and the high growth of science and technology have led to the abundance of dietary life. Due to the western eating habits and convenience of living, the incidence of obesity continues to increase due to the ingestion of instant food and lack of exercise. It is known that about 30 ~ 40% of the modern people are obese, and hypertension, Atherosclerosis, heart disease, diabetes mellitus, and the like.

Obese people are feeling the inferiority due to their body shape, interpersonal relationships are not good, and it is also a disease that causes social problems, but the biggest problem is complications caused by obesity. Obesity causes hyperlipemia, which increases the amount of cholesterol and triglycerides in the blood, resulting in increased incidence of hypertension, cardiovascular disease and stroke, and increases in triglyceride accumulation or peripheral tissue triglyceride in peripheral tissues and abdominal fat tissues Obesity can be caused by insulin resistance and can lead to type 2 diabetes. Obesity is a serious complication of arthritis, respiratory dysfunction, infertility, menstrual irregularities, and malignant tumors. Thus, obesity is regarded not only as a physical and psychological problem, but also as a first risk factor for adult diseases and a serious social problem.

In recent years, as the level of living has increased, interest and expectation for skin beauty have increased, and interest in cosmetics, especially functional beauty products, of women has been increasing. That is, functional cosmetics as a means for protecting the skin from sunlight, wind, rain, etc., which are external stimuli as well as aesthetic improvement means, are attracting attention. Accordingly, there is a growing interest in slimming products that provide hyperlipidemia and skin elasticity. Particularly, as the desire to improve the quality of life is increased by the social environment change such as the improvement of the social status of women and economic independence, interest in beautiful body is also increasing rapidly. Accordingly, the demand for slimming and anti-cellulite cosmetics, which are effective for eliminating excessive subcutaneous fat and promoting skin elasticity, is steadily increasing.

Cellulite occurs in women's skin and subcutaneous fat, and is a phenomenon that becomes rough skin like a rough orange skin due to circulation disorder caused by accumulation of excess fat and waste. The cause of the cellulite is different from the simple obesity but basically it is caused by the increase or enlargement of the fat cell. Therefore, by suppressing and decomposing the fat accumulation in the fat cell, it can be a great help to make a thin and smooth body have.

On the other hand, wangbul ryuhaeng (王不留行, Melandrii Herba) is jangguchae (Melandrium firmum Rohrbach) and other related plants (Caryophyllaceae), when the seeds mature in the summer and autumn, they are dried out in the sun. It has thin and convex nodes, with branches and leaves facing each other and 20 ~ 40cm in length. The leaves are elliptical, the tip is pointed, and has a light yellowish brown color. The peduncle has a bottle-shaped capsule with a length of 1cm and a very small dark brown, black round seed in it. It is distributed in Siberia, China, and Manchuria, and it is distributed in Siberia, China, and Manchuria. It is also known as " It is used medicine. It acts mainly in the liver, promotes milk secretion in the upper part, helps the blood circulation in the blood, loosens the blood in the blood, and functions in the meridians to smooth the circulation. It is known that menstruation has excellent effects on uneven symptoms and boils on the chest area, and it helps to heal wounds in iron products. It is a good medicine for women, but it is forbidden to take it because it can have a bad influence on pregnant women and fetuses. Melandrigenin, gypsogenin, gypsogenic acid, quillaic acid, etc. have been reported as main components of the double-flow phenomenon. In Korean Patent Publication No. 2012-0000246, Korean Patent No. 0686260 discloses a composition for improving liver function and treatment of liver disease comprising an extract of Chrysanthemum japonica, and Korean Patent No. 1165719 discloses a composition for treating chronic hepatitis including an extract of Chrysanthemum japonica as an active ingredient A composition for preventing and treating enlargement of the prostate gland has been disclosed, but a composition containing a long-acting extract having an effect of inhibiting fat accumulation of the present invention has not been disclosed.

The present invention provides a cosmetic composition for prevention or improvement of cellulite containing an extract of Melandrii Herba as an active ingredient and a cosmetic composition for preventing or improving obesity The present invention provides a health functional food composition for preventing or ameliorating obesity, which comprises a pharmaceutical composition for prevention or treatment of diabetes mellitus and an obesity-containing extract as an active ingredient. The extract for hyperlipidemia has an effect of inhibiting fat accumulation and exhibiting antioxidative activity Thereby completing the present invention.

In order to achieve the above object, the present invention provides a cosmetic composition for preventing or improving cellulite containing an extract of Melandrii Herba as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating obesity containing an extract of Melandrii Herba as an active ingredient.

The present invention also provides a health functional food composition for preventing or ameliorating obesity containing an extract of Melandrii Herba as an active ingredient.

The present invention relates to a cosmetic composition for preventing or ameliorating cellulite containing an extract of Melandrii Herba as an active ingredient. The extract of the present invention inhibits fat accumulation and has antioxidant activity. The composition can be applied locally to exhibit a slimming effect, and the above-described long-acting extract can be effectively used as a health functional food or a pharmaceutical composition as a composition for prevention, improvement or treatment of obesity.

FIG. 1 shows the results of confirming cell viability of the extract according to one embodiment of the present invention. Con is a negative control cell that has not been treated.
FIG. 2 shows the results of confirming the effect of inhibiting fat accumulation of the extract of the inulin according to an embodiment of the present invention. Con is a negative control cell that has not undergone any treatment, and MDI is a cell that induced fat accumulation.

The present invention relates to a cosmetic composition for preventing or improving cellulite containing an extract of Melandrii Herba as an active ingredient.

The long-acting extract may be prepared by a method including, but not limited to, the following steps:

1) extracting by adding an extraction solvent to inversion;

2) filtering the extract of step 1); And

3) Concentrating the filtrate obtained in step 2) under reduced pressure and drying to prepare an extract.

In step 1), the extraction solvent is preferably water, a C ₁ -C ₄ lower alcohol or a mixture thereof, more preferably an ethanol extract, more preferably a 70% (v / v) ethanol extract Not limited.

In the above-mentioned production method, the extraction of the double-flow can be performed by any conventional method known in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction. The extraction solvent is preferably extracted by adding 1 to 20 times the volume of the dried upwax, more preferably 7 to 15 times. The extraction temperature is preferably 20 to 50 DEG C, but is not limited thereto. The extraction time is preferably 5 to 20 hours, more preferably 7 to 15 hours, most preferably 10 hours, but not always limited thereto. In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto. It is preferable that the overflow is above the ground part, more preferably it is the fruit part, the stem part or the leaf part, but is not limited thereto.

 The above-mentioned extract of the present invention is characterized by inhibiting fat accumulation, and thus can be used for skin slimming applied locally.

The cosmetic composition for prevention or improvement of cellulite is preferably, but not limited to, a formulation of soap, a cleanser, a lotion, a skin, a lotion, a nutrition lotion, a nutrition cream, a massage cream, an essence or a pack.

The cosmetic composition may further contain, in addition to the active ingredient of the present invention, a lipid, an organic solvent, a solubilizer, a thickening agent and a gelling agent, a softener, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, Any of those commonly used in ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics ≪ RTI ID = 0.0 > cosmetic < / RTI >

The cosmetic composition of the present invention may further comprise functional ingredients other than the above-mentioned effective ingredients. The addition of the raw material which helps the skin health further enhances the effect of the composition of the present invention. In addition, when the raw material that helps the skin health is added, the skin safety due to the combined use, ease of formulation, The stability of the users can be considered. The additional functional ingredient is a functional ingredient disclosed in the Korean Food and Drug Administration. For example, oil, sugar, polyol and the like are not limited to the known raw materials that contribute to skin health.

The present invention also relates to a pharmaceutical composition for preventing or treating obesity, which comprises an extract of Melandrii Herba as an active ingredient.

The pharmaceutical composition of the present invention may further comprise an appropriate carrier, excipient or diluent conventionally used in the production of a pharmaceutical composition, and the pharmaceutical dosage form of the composition according to the present invention may be administered alone or in combination with another pharmaceutically active compound It can also be used as an appropriate assembly.

The pharmaceutical composition according to the present invention can be formulated into oral formulations such as capsules, powders, granules, tablets, suspensions, emulsions, syrups and aerosols, external preparations, suppositories and injections according to conventional methods. Examples of carriers, excipients and diluents that can be contained in the pharmaceutical composition including the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate , Calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. have. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, . In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of liquid formulations for oral use include suspensions, solutions, emulsions and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include withexol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art.

The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.

The present invention also relates to a health functional food composition for preventing or ameliorating obesity containing an extract of Melandrii Herba as an active ingredient.

The composition may be prepared in any form of powder, granule, ring, tablet, capsule, candy, syrup and beverage, but is not limited thereto.

When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method. The active ingredient may be suitably used depending on its intended use (prevention or improvement). Generally, the health functional food composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight based on the raw material, when the food or beverage is produced. However, in the case of long-term intake intended for health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount of more than the above range.

There is no particular limitation on the kind of the health functional food. Examples of the foods to which the health functional food composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, Drinks, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

In addition, the health functional food composition of the present invention can be produced as a food, particularly a functional food. The functional food of the present invention may contain ingredients that are conventionally added. For example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, in the case of a drink, a natural carbohydrate or a flavoring agent may be included as an additional ingredient in addition to the active ingredient. The natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, , Xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).

In addition to the above health functional food composition, it is also possible to use various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in beverages, and the like. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected in the range of 0.01 to 0.1 part by weight based on 100 parts by weight of the health functional food composition of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.

Example  1. Preparation of extract

The ethanol extract of 70% (v / v) was extracted with 30 g of 70% (v / v) ethanol (30 times) 10 times against 3 g of the long-flowing fruit and shaking for 12 hours at room temperature. Then, it was filtered using a filter paper (Whatman No. 1) and concentrated using a vacuum rotary evaporator. The yield of the solubilized components was determined by lyophilization of the extract to determine the weight of the building and then calculating the percentage of the dried material used for the extraction. As a result, a yield of 8.8% was obtained.

Example  2. Cells Survival rate  Confirm

The cell viability of adipocytes was determined by MTT assay. 3T3-L1 cells were cultured in a 24-well culture plate at a concentration of 1 × 10 ⁵ cells / ml for 48 hours, followed by treatment with a heavy-load extract (12.5, 25, 50 μg / ml) for 48 hours. 50 μl of MTT solution (5 mg / ml) was added to each well, followed by incubation for 3 hours to induce a reduction reaction, and formazan crystals formed by adding DMSO were dissolved. Absorbance was measured at 570 nm using a spectrophotometer.

As a result, as shown in FIG. 1, it was confirmed that the extract of the present invention was free from cytotoxicity by confirming that the cell survival rate was almost 100% even after treating the extract of the present invention.

Example  3. Identification of antioxidant activity

1) Total polyphenol content measurement

The content of polyphenol was measured by modifying the method of Gutfiger (1981) which is widely used as an analytical method. 100 희 of the diluted solution was added with 100 F of Folin-Ciocalteau reaction solution, and the mixture was allowed to stand for 3 minutes, followed by addition of 1 ml of 0.7 M Na ₂ CO ₃ solution. After the mixture was reacted for 1 hour, the absorbance was measured at 750 nm using a spectrophotometer. The total polyphenol content of the samples was calculated by preparing a standard curve with tannic acid. As a result, the total polyphenol content of the ascorbic acid extract was 33.08 ± 3.98 mg / g.

2) ABTS Radical  Scavenging activity analysis

The ABTS radical scavenging activity was measured by varying the Blois method. Namely, 7 mM ABTS and 2.45 mM potassium persulfate solution were mixed and allowed to stand overnight in a dark place to form ABTS +. The solution was diluted with distilled water to a molar extinction coefficient of 0.7-0.9 at 734 nm .

100 占 퐇 of diluted ABTS + 占 solution was added to 50 占 퐇 of the extract of the present invention, and the change of absorbance was measured exactly 5 minutes later. The antioxidative activity of ABTS +. Was calculated by the absorbance reduction ratio of the additive and the non-additive of the present invention, and the value of RC ₅₀ , which is a concentration of the sample required to reduce the antioxidative activity of ABTS +, by 50%.

The ABTS radical scavenging activity of the present invention was 15.03 ± 3.90%, and the ABTS radical scavenging activity of vitamin C, which was a positive control, was 15.23%.

3) DPPH Radical  Scavenging activity analysis

DPPH radical scavenging activity was measured by modifying the Blois method. 50 μl of a 0.2 mM DPPH solution was added to 100 μl of the eluate for 10 min, and the change in absorbance was measured at 517 nm. DPPH antioxidant activity was calculated by the absorbance reduction ratio of the sample solution and the non-additive, and the RC ₅₀ value, which is the concentration of the sample required to reduce the DPPH antioxidant activity by 50%.

As a result, DPPH radical scavenging activity was 13.87 ± 1.41%, and vitamin C as a positive control was 10.02% when DPPH extract of the present invention was added.

Example  4. Confirmation of fat accumulation inhibitory effect

1) Cell culture

3T3-L1 cells were purchased from an american type culture collection (ATCC) and cultured in a medium supplemented with 10% FBS (Fetal bovine serum) and 100 μg / ml of penicillin / streptomycin at 37 ° C , And cultured in a 5% CO ₂ incubator.

3T3-L1 cell cultures were suspended in DMEM medium supplemented with 10% newborn calf serum (Newborn calf serum) and 1% penicillin / streptomycin at a concentration of 1 × 10 ⁵ cells / ml and cultured for 48 hours to be confluent. Lt; 0 > C, CO ₂ incubator.

Adipocyte differentiation was induced in the differentiation induction medium (10% FBS, 1% penicillin / streptomycin, MDI [0.5 mM 3-isobutyl-1-methylxanthine, 1 μM Dexamethasone, 5 μg / ml Insulin] And cultured alternately. After induction of differentiation for 2 days, the cells were cultured in 10% FBS-DMEM containing 1 μg / ml of insulin for 2 days. And then replaced with 10% FBS-DMEM four times every 2 days. The treatment of Wangwolyong extract was treated simultaneously with addition of differentiation inducing medium.

2) 3 T3 - L1  Measurement of inhibitory effect of cells on lipid differentiation

3T3-L1 cells were stained with oil red-O to determine the degree of differentiation. In order to observe the differentiated cells, the cultured cells were fixed with 10% formalin / PBS for 5 minutes at room temperature, and then the cells were washed once with 60% isopropanol and dried. Then, oil red-O was added for 30 minutes, and stained. After washing 4 times with distilled water, the fat droplets were observed under a microscope while containing distilled water. After observation, 99% isopropanol was added and dissolved at 180 rpm for 10 minutes and then measured at 520 nm.

As a result, as shown in FIG. 2, the fat accumulation was markedly increased by MDI, and it was confirmed that the fat accumulation increased by MDI was suppressed by the treatment of the ascorbic acid extract. In particular, it was confirmed that the fat accumulation was inhibited by about 40% by the treatment with the extract of Wangwolryeong.

Claims (10)

A cosmetic composition for preventing or improving cellulite containing an extract of Melandrii Herba as an active ingredient. The cosmetic composition for preventing or improving cellulite according to claim 1, wherein the extraction solvent of the long-acting extract is any one selected from water, C ₁ -C ₄ lower alcohols, and mixtures thereof. The cosmetic composition for prevention or improvement of cellulite according to claim 1, wherein the ascorbic acid extract inhibits fat accumulation. The cosmetic composition for prevention or improvement of cellulite according to claim 1, wherein the cosmetic composition for prevention or improvement of cellulite is for skin slimming applied locally. The cosmetic composition for prevention or improvement of cellulite according to claim 1, wherein the cosmetic composition for preventing or improving cellulite is manufactured from any one of a soap, a cleanser, a lotion, a skin, a lotion, a nutrition lotion, a nutrition cream, a massage cream, Wherein the cosmetic composition is a cosmetic composition for preventing or improving cellulite. A pharmaceutical composition for preventing or treating obesity comprising an extract of Melandrii Herba as an active ingredient. The pharmaceutical composition for preventing or treating obesity according to claim 6, which further comprises a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-mentioned extract for rectal administration. [7] The composition according to claim 6, wherein the composition for rectal delivery is prepared from any one of formulations selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups, oral preparations of aerosols, external preparations, suppositories, A pharmaceutical composition for preventing or treating obesity. A health functional food composition for prevention or improvement of obesity containing an extract of Melandrii Herba as an active ingredient. The health functional food composition according to claim 9, wherein the composition is prepared from any one of powder, granule, ring, tablet, capsule, candy, syrup and beverage.

Images